The role of fibrin rich platelets and leukocytes (L-PRF) in the medication-related osteonecrosis of the jaw: report of premaxilla necrosis
DOI:
https://doi.org/10.5935/2525-5711.20210012Keywords:
Platelet-Rich Fibrin, Multiple Myeloma, Diphophosnates, Osteonecrosis, MaxillaAbstract
Bisphosphonates (BPs), antiresorptive and antiangiogenic drugs are used to prevent metastatic bone cancers in prostate cancer, breast cancer and multiple myeloma and to treat osteoporosis and Paget’s disease. Recently, in 2003 the first case of osteonecrosis of the jaws was induced, hitherto by bisphosphonates, but a few years later it was shown that other medications were also responsible for the development of this type of necrosis. Thus, in 2014 there was a change in the name for medication-related osteonecrosis of the jaws (MRONJ). Since then, the treatment for this type of necrosis is quite controversial in the world literature, and there is still no protocol for established treatment, be it clinical or surgical. The objective of this work is to demonstrate the efficacy of platelet and leukocyte- rich fibrin membranes (L-PRF) after curettage of necrotic bone tissue in the management of drug-related jaw osteonecrosis, since they have innumerable biological benefits such as large amount of growth factors and cytokines, hemostatic capacity, angiogenesis capacity, and has been shown to accelerate and improve results in hard and soft tissue wound healing. The patient presented MRONJ and have been treated with surgical necrotic bone debridement, placement of L-PRF in the affected site and primary closure. Patient were followed up clinically and radiographically until total mucosal coverage of the necrotic bone was achieved.
References
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent. 2016 Mar/Apr;6(2):97-104.
Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P. The prevention of medication-related osteonecrosis of the jaw. Dtsch Arztebl Int. 2017 Feb;114(5):63-9.
Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A. Semper-Hogg W. Update MRONJ and perspectives of its treatment. J Stomatol Oral Maxillofac Surg. 2017 Sep;118(4):232-5.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56.
Bilimoria R, Young H, Patel D, Kwok J. The role of piezoelectric surgery and platelet-rich fibrin in treatment of ORN and MRONJ: a clinical case series. Oral Surg. 2018 Oct;11(2):136-43.
Cano-Durán JA, Peña-Cardelles JF, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017 Aug;9(8):e1051-e9.
Alzahrani AA, Murriky A, Shafik S. Influence of platelet rich fibrin on post-extraction socket healing: a clinical and radiographic study. Saudi Dental J. 2017 Oct;29(4):149-55.
Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59.
Brozoski MA, Traina AA, Deboni MCZ, Marques MM, Naclério-Homem MDG. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol. 2012 Mar/Apr;52(2):265-70.
Otto S, Kwon TG, Assaf AT. Definition, clinical features and staging of medication-related osteonecrosis of the jaw. In: Otto S, ed. Medication-related osteonecrosis of the jaws. Berlin: Springer; 2015. p. 43-54.
Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):489-96.
Acikan İ, Aslan N, Durmuş H, Atalay Y, Atılgan S, Yaman F. Surgical treatment of bisphosphonate-associated osteonecrosis of the mandible: report of two cases. J Clin Exp Invest. 2015;6(1):61-4.
Then C, Von Tresckow E, Bartl R, Oduncu FS. Bisphosphonate and denosumab therapy: fields of application. In: Otto S, ed. Medication-related osteonecrosis of the jaws. Berlin: Springer; 2015. p. 17-26.
Maluf G, Pinho MCD, Cunha SRB, Santos PSS, Fregnani ER. Surgery combined with LPRF in denosumab osteonecrosis of the jaw: case report. Braz Dent J. 2016 May/Jun;27(3):353-8.
Gönen ZB, Asan CY. Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin. Cranio. 2017 Sep;35(5):332-6.
Coropciuc RG, Grisar K, Aerden T, Schol M, Schoenaers J, Politis C. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg. 2017 Oct;55(8):787-92.
Del Fabbro M, Gallesio G, Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur J Cancer. 2015 Jan;51(1):62-74.
Longo F, Guida A, Aversa C, Pavone E, Di Costanzo G, Ramaglia L, et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent. 2014;2014:298945.
Lopez-Jornet P, Perez AS, Mendes RA, Tobias A. Medication-related osteonecrosis of the jaw: is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg. 2016 Aug;44(8):1067-72.
Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e37-e44.
Bastami F, Khojasteh A. Use of leukocyte-and platelet-rich fibrin for bone regeneration: a systematic review. Regen Reconstr Rest. 2016 Apr;1(2):47-68.
Zumstein M, Berger S, Schober M, Boileau P, Nyffeler R, Horn M, et al. Leukocyte-and platelet-rich fibrin (L-PRF) for long-term delivery of growth factor in rotator cuff repair: review, preliminary results and future directions. Curr Pharm Biotechnol. 2012 Jun;13(7):1196-206.
Faot F, Deprez S, Vandamme K, Camargos GV, Pinto N, Wouters J, et al. The effect of L-PRF membranes on bone healing in rabbit tibiae bone defects: micro-CT and biomarker results. Sci Rep. 2017 Apr;7:46452.
Hartshorne J, Gluckman H. A comprehensive clinical review of Platelet Rich Fibrin (PRF) and its role in promoting tissue healing and regeneration in dentistry. Int Dent S Afr. 2016;6(5):14-24.
Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg. 2014 Nov;52(9):854-9.
Dinca O, Zurac S, Staniceanu F, Bucur MB, Bodnar DC, Vladan C. Clinical and histopathological studies using fibrin-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Rom J Morphol Embryol. 2014;55(3):961-4.
Published
How to Cite
Issue
Section
License
Copyright (c) 1969 Guilherme Klein Parise, Márcio Vinicius Hurczulack de-Quadros, Evandro Matioski Pereira, Brenda Nazareth Costa, Cleverson Patussi, Juliana Lucena Schussel, Laurindo Moacir Sassi
This work is licensed under a Creative Commons Attribution 4.0 International License.
